Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma.

Immunity, inflammation and disease - 1 Jun 2020

Alikhanyan Kristina, Chen Yuanyuan, Kraut Simone, Sotillo Rocio

Abstract excerpt

INTRODUCTION: Alveolar macrophages (AMs) are critical in the development of lung adenocarcinoma driven by epidermal growth factor receptor (EGFR) mutations. Whether interstitial macrophages (IMs) are also involved in lung tumorigenesis is still unclear. Thus, the aim of this study is to evaluate the role of both AM and IM in the development of EGFR mutant driven lung adenocarcinoma. METHODS: We used the EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Bronchoalveolar Lavage Fluid

Share to CD8-Positive T-Lymphocytes

Share to Macrophage Activation

Share to Macrophages, Alveolar

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 32125091
DOI: 10.1002/iid3.293
PMCID: PMC7212197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma.PMID 32125091Read ↗

Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar MacrophagesSemantic proximity Read ↗

Macrophages, Inflammation, and Lung Cancer.Semantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.Semantic proximity Read ↗

Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to TalkSemantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumorsSemantic proximity Read ↗

Modulating Tumor-Associated Macrophages through CSF1R Inhibition: A Potential Therapeutic Strategy for HNSCCSemantic proximity Read ↗

KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype.Semantic proximity Read ↗

DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.Semantic proximity Read ↗

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer.Semantic proximity Read ↗

Unmasking the lung cancer epigenome.Semantic proximity Read ↗

Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung CancerSemantic proximity Read ↗

Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.